RBC Capital raised the firm’s price target on Biogen (BIIB) to $219 from $208 and keeps an Outperform rating on the shares after its Q2 earnings beat. The firm is positive on the company’s strong performance from Leqembi and the MS franchise – even allowing for some one-time benefits – along with solid sales across their other programs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $142 from $143 at BofA
- Promising Developments in Biogen’s IgAN Treatments Drive Buy Rating
- Biogen price target raised to $135 from $125 at Citi
- Biogen price target raised to $194 from $187 at H.C. Wainwright
- Cautious Hold on Biogen Amid Modest Growth Prospects and Uncertain Pipeline